

Disclosures

Mark Freedman has received honoraria or consulting fees from Actelion, Bayer HealthCare, Biogen, Chugai, EMD Canada, Genzyme, Hoffmann-La Roche, Merck Serono, Novartis, Sanofi-Aventis, and Teva Canada Innovation; has served on an advisory boards for Actelion, Bayer HealthCare, Biogen, Hoffmann-La Roche, Merck Serono, Novartis, Opexa, and Sanofi-Aventis; and has participated in a speakers' bureau for Genzyme. Eva Havrdova has received honoraria from Actelion, Biogen, Celgene, Merck, Novartis, Sanofi Genzyme and Teva. Patricia K Coyle has received consulting fees from Accordant, Alexion, Bayer, Biogen Idec, Celgene, Genentech/Roche, Genzyme/Sanofi, GlaxoSmithKline, Mylan, Novartis, Serono, and TG Therapeutics; research support from Actelion, Alkermes, Corrona LLD, Genentech/Roche, MedDay, NINDS, Novartis, PCORI. Carlo Pozzilli has served on scientific advisory boards for Novartis, Merck, Biogen, Sanofi, Genzyme, Teva, Actelion and funding for travel and speaker honoraria from Biogen, Teva, Sanofi Genzyme, Actelion and Novartis, and research support from Biogen, Teva, Novartis and Genzyme. Alexandre Lemle, Michel Burcklen, Brian Hennessy, Tatiana Scherz, Andrea Vaclavkova are employees of Actelion, Part of Janssen Pharmaceutical companies of Johnson & Johnson and hold stock in Johnson & Johnson. Anna Larbalestier is a contractor for Actelion, Part of Janssen Pharmaceutical Companies. Tomas Olsson has received advisory board and/or lecture honoraria, and/or unrestricted MS research grants from Biogen, Novartis, Merck, Genzyme, Allmiral, AstraZeneca and Roche.